Want to see TMO full AI Analyst Report?
TMO Stock Chart & Stats
$628.15
-$4.06(-0.71%)
At close: 4:00 PM EDT
$628.15
-$4.06(-0.71%)
Day’s Range― - ―
52-Week Range$435.27 - $711.85
Previous CloseN/A
Volume2.94M
Average Volume (3M)2.51M
Market Cap
$262.22B
Enterprise Value$285.86B
Total Cash (Recent Filing)$6.06B
Total Debt (Recent Filing)$41.37B
Price to Earnings (P/E)37.3
Beta0.69
Next Earnings
Feb 04, 2027EPS Estimate
7.14Next Dividend Ex-DateN/A
Dividend Yield0.26%
Share Statistics
EPS (TTM)18.99
Shares Outstanding369,747,280
10 Day Avg. Volume2,795,472
30 Day Avg. Volume2,507,767
Financial Highlights & Ratios
PEG Ratio4.54
Price to Book (P/B)4.08
Price to Sales (P/S)4.89
P/FCF Ratio34.62
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue6.04
Enterprise Value/Gross Profit14.57
Enterprise Value/Ebitda25.43
Forecast
1Y Price Target
$758.47Price Target Upside20.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)25.26
Revenue Forecast (FY)$48.00B
Bulls Say, Bears Say
Bulls Say
Diversified Recurring-revenue ModelRevenue combines repeat-purchase consumables, service contracts and workflow products with instruments that generate downstream pull-through. This mix, spanning pharma, research, clinical and industrial customers, supports recurring demand and reduces reliance on any single end market.
Strong Cash GenerationSubstantial operating and free cash flow, with strong conversion from earnings, gives Thermo Fisher resources to fund capital investment, product development, debt repayment and shareholder returns. This cash-generation profile supports resilience and strategic flexibility across business cycles.
Innovation And Bioproduction PositioningProduct innovation across AI-enabled microscopy, sequencing, diagnostics and mass spectrometry broadens Thermo Fisher’s capabilities. Its stated leadership in bioproduction technologies also aligns the portfolio with long-term pharmaceutical and biotechnology manufacturing needs.
Bears Say
Meaningful LeverageMeaningful debt and elevated leverage increase fixed financial obligations and reduce flexibility relative to a lightly levered balance sheet. They can constrain capital allocation and make the company more sensitive to slower growth, refinancing conditions or sustained interest expense.
Muted Reagent DemandWeakness in bioscience and genetic science reagents limits growth in a recurring, consumables-oriented part of the portfolio. If biotech spending takes longer to recover, subdued demand could restrain organic growth and leave more reliance on stronger bioproduction and service areas.
Specialty Diagnostics WeaknessA reported decline in Specialty Diagnostics shows that performance is uneven across Thermo Fisher’s businesses despite broader company growth. Continued weakness in this segment could offset gains elsewhere and require stronger execution to restore momentum in diagnostics.
TMO FAQ
What was Thermo Fisher’s price range in the past 12 months?
Thermo Fisher lowest stock price was $435.27 and its highest was $711.85 in the past 12 months.
What is Thermo Fisher’s market cap?
Thermo Fisher’s market cap is $262.22B.
When is Thermo Fisher’s upcoming earnings report date?
Thermo Fisher’s upcoming earnings report date is Feb 04, 2027 which is in 96 days.
How were Thermo Fisher’s earnings last quarter?
Thermo Fisher released its earnings results on Oct 21, 2026. The company reported $6.68 earnings per share for the quarter, beating the consensus estimate of $6.403 by $0.277.
Is Thermo Fisher overvalued?
According to Wall Street analysts Thermo Fisher’s price is currently Undervalued.
Does Thermo Fisher pay dividends?
Thermo Fisher pays a Quarterly dividend of $0.47 which represents an annual dividend yield of 0.26%. See more information on Thermo Fisher dividends here
What is Thermo Fisher’s EPS estimate?
Thermo Fisher’s EPS estimate is 7.14.
How many shares outstanding does Thermo Fisher have?
Thermo Fisher has 369,747,280 shares outstanding.
What happened to Thermo Fisher’s price movement after its last earnings report?
Thermo Fisher reported an EPS of $6.68 in its last earnings report, beating expectations of $6.403. Following the earnings report the stock price went up 0.967%.
Which hedge fund is a major shareholder of Thermo Fisher?
Currently, no hedge funds are holding shares in TMO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Thermo Fisher Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$758.47 (20.75% Upside)
$758.47 (20.75% Upside)
Blogger Sentiment
Bullish
TMO Sentiment 80%
Sector Average 64%
Sector Average 64%
Hedge Fund Trend
Increased
By 3.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $12.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 6.1%
Last 30 Days ▲ 6.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.46%
12-Months-Change
Fundamentals
Return on Equity
13.31%
Trailing 12-Months
Asset Growth
10.88%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Thermo Fisher
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors. The Analytical Instruments segment delivers a variety of precision instruments, consumables, software, and support services to pharmaceutical, biotechnology, academic, governmental, environmental, and industrial research environments, as well as clinical laboratories. The Specialty Diagnostics segment offers an array of diagnostic tools, including liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, alongside calibrators, controls, protein detection assays, and accompanying instruments. This also features the creation and distribution of complete blood test systems to aid in the clinical diagnosis and monitoring of allergies, asthma, and autoimmune diseases. Furthermore, it provides dehydrated and prepared culture media, specimen collection and transport systems, related instrumentation and consumables, human leukocyte antigen (HLA) typing and testing crucial for the organ transplant sector, and other healthcare products. Lastly, the Laboratory Products and Biopharma Services segment supplies laboratory equipment, serves the research and safety markets through its channels, and offers extensive pharmaceutical services, encompassing clinical research support. The company's products and services are distributed through a dedicated direct sales team, customer service professionals, online commerce platforms, and a network of third-party distributors. Its recognized brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Thermo Fisher Scientific Inc. was established in 1956 and is headquartered in Waltham, Massachusetts.
TMO Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly positive. Thermo Fisher delivered broad-based revenue, profit, margin, cash flow, and organic growth improvements; exceeded prior guidance; raised full-year revenue, EPS, and free cash flow guidance; and reported continued momentum in pharma, biotech, analytical instruments, AI, clinical research, and bioproduction. The main challenges were flat academic and government revenue, a decline in reported Specialty Diagnostics revenue, muted reagent demand, unfavorable mix, and some Pharma Services timing between the third and fourth quarters.View all TMO earnings summariesTMO Revenue Breakdown
54.01% Laboratory Products and Biopharma Services
22.46% Life Sciences Solutions
17.40% Analytical Instruments
10.52% Specialty Diagnostics

TMO Stock 12 Month Forecast
Average Price Target
$758.47
▲(20.75% Upside)
Technical Analysis
Ownership Overview
0.13% Insiders
25.33% Mutual Funds
4.94% Other Institutional Investors
48.41% Public Companies and Individual Investors










